Compass Pathways.
mental health care company
- Reports this week
- 0
- Active events
- 0
- Connections
- 39
What's happening
Earlier this month
One to three months ago
-
Johnson & Johnson and Compass Pathways are both involved in the advanced psychedelic therapy market, currently submitting applications for COMP360 approval.Some support1 report
-
Guy Goodwin has been appointed Chief Medical Officer at Compass Pathways.Some support1 report
-
Compass Pathways announced that its Phase 3 trial for COMP360 successfully met the primary endpoint.Some support4 reports
-
Compass Pathways ADR trading on the Nasdaq stock exchange.Some support1 report
-
Compass Pathways, NeuroStar, and Greenbrook are facing mixed business signals regarding their business units, with both revenue growth and decline reported.Some support1 report
Gone quiet
No new reports in 90+ days-
Compass Pathways and LabCorp are two companies operating within the healthcare sector.Some support1 report
-
FDA reviews potential accelerated pathways for approval for Compass Pathways.Well supported4 reports
-
Compass Pathways established its operational footprint as of July 2025, including headquarters in London, offices in New York, and Breakthrough Therapy designation from the FDA.Some support3 reports1 development inside
-
RBC Capital Markets noted disappointing trial results for Compass Pathways, whose drug faces competition from Johnson & Johnson's Spravato.Speculative1 report
-
Compass Pathways received a Zacks rating upgrade on July 9, 2025, due to rising earnings estimates and positive outlook.Speculative1 report
-
A conference (PS2025) was held at the Colorado Convention Center in Denver on July 16, 2025, featuring major announcements from the psychedelic industry.Some support1 report
No events began in the chosen period. Widen it, or reset.
Around Compass Pathways this week
News at the entities that move Compass Pathways most-
FDA StructuralFDA issued a warning letter to NeoGen regarding a product quality defect on October 7, 2026.Moves Compass Pathways
-
Drug Enforcement Administration StructuralDEA conducted investigations and seized properties in Aiken, Georgia, and the Midlands region.Moves Compass Pathways
-
Morgan Stanley Mentioned togetherAmazon is attempting to challenge Google's search dominance while Morgan Stanley reports highlight shopper behavior trends.Moves Compass Pathways
-
MarketBeat Mentioned togetherMarketBeat used its stock screener tool to highlight Walmart.Moves Compass Pathways
-
Cathie Wood TransactionalThe Hong Kong Web3 Festival 2027 is being held in Hong Kong to examine developments in the digital asset industry.Moves Compass Pathways
-
TD Cowen Mentioned togetherTD Cowen is based in Toronto.Moves Compass Pathways
Connections
The 20 strongest of 39, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Kabir Nath Structural
Kabir Nath holds the formal role of CEO at Compass Pathways.
-
FDA Structural
Compass Pathways relies on the FDA for regulatory designations, submissions, and market approval of its therapies.
-
Drug Enforcement Administration Structural
Compass Pathways' launch and drug availability are dependent on regulatory rescheduling by the Drug Enforcement Administration.
-
Guy Goodwin Structural
Guy Goodwin holds the role of Chief Medical Officer at Compass Pathways.
-
Nasdaq Structural
Compass Pathways utilizes Nasdaq's platform for ADR trading.
-
Morgan Stanley Mentioned together
Morgan Stanley has provided 'overweight' ratings and lifted price targets for Compass Pathways.
-
Raymond James Financial Transactional
Raymond James Financial issued a buy rating on Compass Pathways stock.
-
Royal Bank of Canada Mentioned together
Royal Bank of Canada provides financial analysis, including price targets and ratings, for Compass Pathways.
Show all 20 connections
-
Cathie Wood Transactional
Cathie Wood purchased shares in Compass Pathways as part of her investment strategy.
-
MarketBeat Mentioned together
MarketBeat aggregates and reports consensus stock ratings and price targets for Compass Pathways.
-
Johnson & Johnson Operational
Johnson & Johnson and Compass Pathways are actively competing in the advanced psychedelic therapy market.
-
TD Cowen Mentioned together
TD Cowen has provided a 'buy' rating on Compass Pathways, indicating a professional market assessment.
-
Mental Health America Operational
Mental Health America is observed amplifying a campaign related to Compass Pathways' efforts.
-
Jefferies Financial Group Mentioned together
Jefferies Financial Group provided market coverage of Compass Pathways by restating a buy rating on its stock.
-
LabCorp Mentioned together
Both Compass Pathways and LabCorp are identified as medical companies operating within the healthcare sector.
-
London Shared context
Compass Pathways is headquartered and operates within London.
-
Robert F. Kennedy Jr. Shared context
Kennedy has criticized corporate influence within the health sector, where Compass Pathways operates.
-
New York City Shared context
Compass Pathways maintains offices in New York City, establishing a positional link.
-
RBC Capital Markets Mentioned together
No direct coupling or co-mention between RBC Capital Markets and Compass Pathways was observed in the provided evidence.
-
National Alliance on Mental Illness Mentioned together
The provided evidence does not describe any relationship or coupling between National Alliance on Mental Illness and Compass Pathways.
History
Events by the month they beganSeptember 2026
2 eventsAugust 2026
2 eventsJuly 2026
2 eventsShow 1 earlier month
June 2026
7 events- Kabir Nath was appointed CEO of Compass Pathways, and Justin Gover joined the company's Board of Directors.
- Compass Pathways announced that its Phase 3 trial for COMP360 successfully met the primary endpoint.
- FDA reviews potential accelerated pathways for approval for Compass Pathways.
- Compass Pathways established its operational footprint as of July 2025, including headquarters in London, offices in New York, and Breakthrough Therapy designation from the FDA.
- RBC Capital Markets noted disappointing trial results for Compass Pathways, whose drug faces competition from Johnson & Johnson's Spravato.
- Compass Pathways received a Zacks rating upgrade on July 9, 2025, due to rising earnings estimates and positive outlook.
- A conference (PS2025) was held at the Colorado Convention Center in Denver on July 16, 2025, featuring major announcements from the psychedelic industry.